Browse drugs

…CI −0.53 to 0.86 events per 1000 person-years) or compared with DPP-4is (HR 0.94; 95% CI 0.71 to 1.24, rate difference −0.18; 95% CI −0…

…nsporter 2 inhibitors, and insulin, as well as length of use of metformin, sulfonylureas, thiazolidinediones, dipeptidyl peptidase 4 inhi…

…ever, these studies did not employ suitable active comparators. Metformin is often prescribed as first-line therapy in T2DM management, w…

…h new generation agents and longer duration: 3 year exposure to semaglutide or tirzepatide gave an absolute risk difference of −4.71 percen…

…Glucagon-like peptide 1 receptor agonists (GLP-1RAs) improve glycaemic control,1 promote weight loss,2 delay progre…

…g reports of suicidal ideation and behaviors in patients taking GLP-1 RAs. This study assessed a potential association with intentional s…

… (SGLT2i: adjusted median OR (aMOR) 1.29 (95% CI 1.23 to 1.36); GLP-1 RA: aMOR 1.48 (95% CI 1.37 to 1.62)). Treating all patients would …

…th a combination of sodium glucose co-transporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, high-dose lipid-lowering, antihypertensive and antithrombotic …

…e estimated the comparative effect of incretin-based therapies (GLP-1RA and dipeptidyl-peptidase-4 inhibitors (DPP-4i)) versus sodium-g…

…have been developed or approved for treatment of SLD, including thyroid hormone receptor β agonists, glucagon-like peptide 1 receptor agonists and fibroblast growt…

…ugh sustained remission is untested. Recently introduced drugs (sodium-glucose cotransporter 2 inhibitors and newer glucagon-like peptide 1 receptor agonists) offer prom…